Boston Scientific Corporation entered into new credit facilities with a group of lenders led by Wells Fargo Bank, National Association as administrative agent, including a $3.0 billion revolving credit agreement maturing Feb. 26, 2031, a $2.0 billion 364-day revolving credit agreement, and a $6.0 billion 364-day delayed draw term loan facility intended to help fund its planned acquisition of Penumbra, Inc. The agreements include interest rates tied to Term SOFR or other benchmark rates plus margins based on the company’s credit rating, along with facility and certain ticking fees, and require compliance with a maximum leverage ratio covenant. Boston Scientific also terminated its prior revolving credit agreement originally dated May 10, 2021.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boston Scientific Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000885725-26-000017), on February 26, 2026, and is solely responsible for the information contained therein.